11月12日,礼来中国宣布其穆优达(奥氟格列隆钙片,以下简称“奥氟格列隆”)获得国家药品监督管理局批准为1类新药上市,适用于在控制饮食和增加运动基础上,用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。奥氟格列隆成为国内首个获批用于成人体重管理的口服GLP-1受体激动剂。记者|林志吟编辑|瑜见
Source Link11月12日,礼来中国宣布其穆优达(奥氟格列隆钙片,以下简称“奥氟格列隆”)获得国家药品监督管理局批准为1类新药上市,适用于在控制饮食和增加运动基础上,用于肥胖或超重并伴有至少一种体重相关合并症的成人体重管理。奥氟格列隆成为国内首个获批用于成人体重管理的口服GLP-1受体激动剂。记者|林志吟编辑|瑜见
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.